More recently, results from the PrE0102 clinical trial showed that combined everolimus and the estrogen receptor downregulator, fulvestrant, improved PFS more compared to the fulvestrant alone (10.3 vs. 5.1 months, p = 0.02) in ER+ advanced breast cancer patients previously treated with an AI [32]. Here, ESR1 is linked to breast carcinoma.